Standardized practice for the administration of rectal lactulose in hospitalized patients with hepatic encephalopathy

Mary Beth Tucker, RN, MN, CEN, CCNS
Critical Care Clinical Nurse Specialist
Piedmont Hospital, Atlanta, GA

**Problem and Significance**
Lactulose, a non-absorbable disaccharide, is used as a first-line agent for the treatment of hepatic encephalopathy. Oral lactulose may be administered; however, research has shown that the pH of the stool decreases more rapidly, and there is a significantly decreased time in lowering ammonia levels when administered rectally. The manufacturer’s recommendation for preparing lactulose for rectal administration is to mix 300 mL of lactulose solution in 700 mL of water or physiologic saline. This solution is then given via an enema and the patient is to retain this for 30 to 60 minutes. Many of these patients are in impending coma or coma as a result of their disease process and do not have the mental faculties required to hold this amount of fluid for the prescribed time. This often leads to fecal incontinence, bed soiling, and failure to absorb the medication effectively. Skin breakdown may result from frequent stooling, especially due to the acidity of the stool after lactulose administration. Even with oral or nasogastric administration, fecal incontinence, bed soiling, and potential for skin breakdown may occur.

**Process Improvement**
Historically at our hospital, the medication was administered via a standard enema bag, and then a large rigid urinary tube was inserted into the rectum to collect the stool. The use of this tube was off-label. Aware that this was not best practice, we collaborated with a colorectal surgeon, a hepatologist, and pharmacist to explore our options. We recently began using an indwelling bowel catheter system* to manage incontinent stool and we decided to explore the medication administration option available with this device. Over time, we discovered most of these patients were able to hold approximately 300 mL for 15 to 20 minutes at a time. We began to mix the lactulose solution in a smaller amount of normal saline in order to decrease the amount of volume the patient would have to retain, without decreasing the dose. Our multidisciplinary team developed a nursing procedure and medication order set to standardize the administration of rectal lactulose for the encephalopathic patient in our hospital.

*ActiFlo indwelling bowel catheter system
“This standardization has allowed us to consistently deliver the best care with regard to lactulose administration for this group of patients.”

Results
At our liver transplant center, we care for acutely ill hepatic failure patients, many of whom suffer from hepatic encephalopathy prior to receiving their transplants. As a result of this multidisciplinary effort, we have been able to standardize our order set and protocol. This standardization has allowed us to consistently deliver the best care with regard to lactulose administration for this group of patients.

How Lactulose Works with Hepatic Encephalopathy
Lactulose is a synthetic disaccharide that acidifies the colon as it is degraded. This acidification process results in the retention of ammonia in the colon as the ammonium ion (NH₄⁺). As this process occurs, the colon becomes more acidic than the blood, causing the migration of ammonia from the blood into the colon. The colonic contents convert the ammonium ion (NH₄⁺) to the ammonium ion (NH₄⁺), trapping it and preventing its absorption. The trapped ammonium ion is then expelled in the stool.
Administration of Enema/Medications Using the ActiFlo Indwelling Bowel Catheter System*

CAUTION: Prior to using ActiFlo indwelling bowel catheter system, be sure to read the entire ActiFlo indwelling bowel catheter system Instructions for Use package insert supplied with the product.

NOTE: The CLEAR connector (IRRIG/Rx) should be flushed with 20 mL of water before and after the administration of enema/medications. Viscous enema/medications may require dilution to facilitate administration through the irrigation lumen.

1. Inflate the intraluminal balloon with 25 mL of air via the RED connector (STOP FLOW 25 mL AIR). Disconnect the syringe.

2. Open the CLEAR connector (IRRIG/Rx) and flush the irrigation lumen with 20 mL lukewarm water (26º-38º C, 80º-100º F), then disconnect the syringe and close the connector.

3. Connect the medication syringe or medication bag to the CLEAR connector (IRRIG/Rx) and slowly inject the solution or allow it to flow in by gravity.

WARNING: Do not connect mechanical pumping devices to CLEAR connector (IRRIG/Rx).

4. Flush the CLEAR connector (IRRIG/Rx) with 20 mL lukewarm water (26º-38º C, 80º-100º F), then disconnect the syringe and close the connector.

5. Allow the enema/medication to dwell for the desired retention time as prescribed by the physician.

6. Using the syringe, completely aspirate the air from the intraluminal balloon via the RED connector (STOP FLOW 25 mL AIR). Disconnect the syringe and confirm that the pilot balloon is fully collapsed.

WARNING: Do not leave intraluminal balloon inflated in an unattended patient.

References

Note: Use of Lactulose as described in this article is one option used by a particular hospital. No determination is made in the article as to the effectiveness of using Lactulose per the dilution and time intervals described by the hospital. Clinicians and hospitals should make an independent decision as to whether the hospital’s approach is appropriate for them and their patients.

*ActiFlo indwelling bowel catheter system, Hollister Incorporated, Libertyville, IL
ActiFlo Indwelling Bowel Catheter System
Product Information

NON STERILE: The ActiFlo indwelling bowel catheter is constructed primarily of silicone materials. All system components are latex-free. Single use only.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician or other healthcare practitioner licensed under state law to order this product. Refer to the complete ActiFlo indwelling bowel catheter system Instructions for Use supplied by the manufacturer for directions on how to properly use this product.

INTENDED USE: The ActiFlo indwelling bowel catheter system is intended for diversion of fecal matter to minimize external contact with the patient's skin, to facilitate the collection of fecal matter for patients requiring stool management, to provide access for colonic irrigation, and to administer enema/medications.

CONTRAINDICATIONS
• Do not use in patients having known sensitivities or allergies to the materials used in this device.
• Do not use if the patient's distal rectum cannot accommodate the inflated volume of the retention cuff or if the distal rectum/anal canal is severely strictured (eg., secondary to tumor, inflammatory condition, radiation injury, scarring).
• Do not use on patients having impacted stool.
• Do not use on patients with a recent (less than 6 weeks old) rectal anastomosis, or a recent (less than 6 weeks old) anal or sphincter reconstruction.
• Do not use on patients with compromised rectal wall integrity (eg., ischemic proctitis).
• Do not connect irrigation bag to an IV.
• Do not use irrigation bag for enteral feeding.

WARNINGS
(Failure to comply with the following warnings may result in patient injury)
• Do not use if package is open or damaged.
• Do not use improper amount or type of fluids for irrigation or cuff/balloon inflations. NEVER use hot liquids.
• Do not over inflate retention cuff or stop-flow balloon.
• Inflation of the stop-flow balloon causes complete catheter occlusion. Do not leave stop-flow balloon inflated in an unattended patient. To verify complete deflation of the stop-flow balloon, aspirate all air until RED connector (STOP FLOW 25 mL AIR) pilot balloon is collapsed when the syringe is removed from the connector.
• Use only gravity or slow manual irrigation. Do not connect manual pumping devices to catheter irrigation lumen. Do not irrigate patient with compromised intestinal wall integrity.
• Extreme caution should be exercised in patients at risk for the development of toxic megacolon. Occluding the tube by inflating the stop-flow balloon could aggravate this situation.
• Perform irrigations, and enema/medication administrations, via the CLEAR connector (IRRIG/Rx) AND NOT via the BLUE connector (CUFF 35–40 mL H2O) or RED connector (STOP FLOW 25 mL AIR).
• Blood per rectum should be investigated to ensure no evidence of pressure necrosis from the device. Discontinue use of the device if evident.
• Abdominal distention that occurs while using the device should be investigated.
• Excessive prolonged traction on the catheter, resulting in the retention cuff migrating into the anal canal, could result in temporary or permanent clinical sphincter dysfunction, or catheter expulsion.

PRECAUTIONS
• Do not sterilize.
• The ActiFlo indwelling bowel catheter system is not intended for use longer than 29 days.
• Caution should be used in patients who may bleed easily due to anticoagulant/antiplatelet therapy or underlying disease conditions. Immediately consult a physician if rectal bleeding is suspected.
• The ActiFlo indwelling bowel catheter system is not recommended for pediatric use.
• To avoid damage to retention cuff or stop-flow balloon, DO NOT contact either with ANY sharp edge including the enclosed lubricating jelly packets.
• The ActiFlo indwelling bowel catheter system may not be effective in individuals who have had their distal rectum significantly altered by surgical resection or reconstruction.
• Patients with very weak sphincter function may expel the catheter under normal use, or sphincter function.
• Caution should be observed in patients whose rectum may be altered by stricture due to radiation or affected with radiation proctitis.
• Patients with severe tenesmus, or patients who experience tenesmus or severe pain after insertion of device, may not tolerate the catheter in place.

ADVERSE EVENTS
• The following adverse events may be associated with the use of any rectal device:
  • Perforation
  • Pressure necrosis
  • Loss of sphincter tone
  • Obstruction
  • Infection
  • Excessive leakage of fecal contents

Hollister Incorporated
2000 Hollister Drive
Libertyville, Illinois 60048 USA
For detailed clinical questions: 1.888.740.8999
For orders only: 1.800.323.4060
Distributed in Canada by Hollister Limited
95 Mary Street
Aurora, Ontario L4G 1G3
1.800.263.7400
www.hollister.com
Hollister and logo, and ActiFlo are trademarks of Hollister Incorporated. All other trademarks and copyrights, are the property of their respective owners.
©2012 Hollister Incorporated.
910954-1112